UB Paderborn / Katalog / Suche / in CDI

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

British journal of cancer, 2012-02, Vol.106 (4), p.633-637

2012

Volltextzugriff (PDF)

Combined Oral Topotecan plus Carboplatin in Relapsed or Advanced Cervical Cancer: A GINECO Phase I-II Trial

Anticancer research, 2012-03, Vol.32 (3), p.1045-1049

2012

Volltextzugriff (PDF)

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

The New England journal of medicine, 2021-12, Vol.385 (23), p.2123-2131

2021

Volltextzugriff (PDF)

Who needs a comprehensive geriatric assessment? A French Onco-Geriatric Screening tool (OGS)

Journal of geriatric oncology, 2011-04, Vol.2 (2), p.130-136

2011

Volltextzugriff (PDF)

793P Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)

Annals of oncology, 2023-10, Vol.34, p.S532-S532

2023

Volltextzugriff (PDF)

Validation of a French screening tool to identify older patients needing a Comprehensive Geriatric Assessment in the management of their cancer

Critical reviews in oncology/hematology, 2008-10, Vol.68, p.S30-S30

2008

Volltextzugriff (PDF)

573P Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial

Annals of oncology, 2022-09, Vol.33, p.S809

2022

Volltextzugriff (PDF)

741P Immune features of high-grade ovarian cancer associated with exceptional disease free survival (DFS): An analysis from VIVROVAIRE, a GINECO/GINEGEPS study

Annals of oncology, 2021-09, Vol.32, p.S739-S739

2021

Volltextzugriff (PDF)

Imagerie des tumeurs endocrines digestives : le point de vue du radiologue

Médecine nucléaire : imagerie fonctionelle et métabolique, 2009-11, Vol.33 (11), p.695-705

2009

Volltextzugriff (PDF)

Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy

Annals of oncology, 2000-10, Vol.11 (10), p.1289-1294

2000

Volltextzugriff (PDF)

812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial

Annals of oncology, 2020-09, Vol.31, p.S614-S614

2020

Volltextzugriff (PDF)

Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study

Clinical breast cancer, 2018-12, Vol.18 (6), p.e1311-e1321

2018

Volltextzugriff (PDF)

1036P - Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

Annals of oncology, 2019-10, Vol.30, p.v423-v423

2019

Volltextzugriff (PDF)

Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

Annals of oncology, 2019-10, Vol.30, p.v415

2019

Volltextzugriff (PDF)

1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

Annals of oncology, 2019-10, Vol.30, p.v415-v415

2019

Volltextzugriff (PDF)

Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

Annals of oncology, 2019-10, Vol.30, p.v423

2019

Volltextzugriff (PDF)

1032 Strong association between pathological response to neoadjuvant chemotherapy, TILs and modeled CA125 KELIM in ovarian carcinomas: CHIVA trial, GINECO

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A340-A340

2021

Volltextzugriff (PDF)

Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

Annals of oncology, 2019-10, Vol.30, p.v783-v784

2019

Volltextzugriff (PDF)

1945P - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

Annals of oncology, 2019-10, Vol.30, p.v783-v784

2019

Volltextzugriff (PDF)

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

European journal of cancer (1990), 2013-12, Vol.49 (18), p.3831-3838

2013

Volltextzugriff (PDF)

CA-I25 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

British journal of cancer, 2012, Vol.106 (4), p.633-637

2012

Volltextzugriff (PDF)

1036PTumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1016PSurrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1945PComparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

Combined Oral Topotecan plus Carboplatin in Relapsed or Advanced Cervical Cancer: A GINECO Phase I-II Trial

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

Who needs a comprehensive geriatric assessment? A French Onco-Geriatric Screening tool (OGS)

793P Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)

Validation of a French screening tool to identify older patients needing a Comprehensive Geriatric Assessment in the management of their cancer

573P Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial

741P Immune features of high-grade ovarian cancer associated with exceptional disease free survival (DFS): An analysis from VIVROVAIRE, a GINECO/GINEGEPS study

Imagerie des tumeurs endocrines digestives : le point de vue du radiologue

Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy

812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial

Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study

1036P - Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

1032 Strong association between pathological response to neoadjuvant chemotherapy, TILs and modeled CA125 KELIM in ovarian carcinomas: CHIVA trial, GINECO

Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

1945P - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

The CHIVA study: a GINECO randomized double blind phase II trial of nintedanib versus placebo with the neo-adjuvant chemotherapy (NACT) strategy for patients (pts) with advanced unresectable ovarian cancer (OC). Report of the interval debulking surgery (IDS) safety outcome

CA-I25 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

1036PTumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

1016PSurrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

1945PComparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

Suchergebnisse filtern